DUBLIN–(BUSINESS WIRE)–The “Pruritus Therapeutics Market By Drug type, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.
The global pruritus therapeutics market was valued at $7,849.4 million in 2021, and is projected to reach $11,186.15 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.
Medical professionals have utilized corticosteroids as a topical dosage form for treating pruritus for many years. The first-line pharmacological therapy for pruritus and associated skin itch diseases such as AD, allergic contact dermatitis, and lichen planus is corticosteroids. Pruritus, a common sign of autoimmune and inflammatory skin conditions, can be extremely uncomfortable and negatively affect a patient’s quality of life. Moisturizers, emollients, and barrier repair creams usually lessen pruritus by enhancing barrier function.
Leading market players are significantly investing in research and development to create innovative pruritus therapies. Investments are also being made to advance existing therapeutics. In addition, launching new medications and building a strong product pipeline is the major focus of key players. Moreover, owing to their low cost and convenience of availability, over-the-counter topical medicines are in high demand. As a result, patients are turning more frequently to over-the-counter treatments. These drivers provide a favorable environment for increasing sales of pruritus products and for growth of the overall market. However, lack of knowledge regarding cause of the disease creates hindrance to the market. Moreover, patent expiry of various pruritus therapeutic products provide a greater opportunity for market players to grow their business.
Key Market Segments
By Drug type
Corticosteroids
Antihistamines
Local Anesthetics
Immunosuppressant
Others
By Disease Type
Atopic Dermatitis
Allergic Contact Dermatitis
Urticaria
Others
By Distribution Channel
Hospital Pharmacies
Drug stores Retail Pharmacies
Route of Administration
Oral
Parenteral
Topical
Online providers
By Region
North America
U.S.
Canada
Mexico
Europe
France
UK
Italy
Spain
Rest of Europe
Germany
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
AbbVie Inc.
Amgen Inc.
Bausch Health Companies Inc.
Cara therapeutics, Inc.
Cipla Ltd.
Eilly Lilly and company
Evelo Biosciences
Galderma S.A.
LEO Pharma
MC2 therapeuitics
Novan, Inc
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc
Sanofi
Trevi therapeutics
Viatris Inc. (Mylan NV)
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: PRURITUS THERAPEUTICS MARKET, BY DRUG TYPE
CHAPTER 5: PRURITUS THERAPEUTICS MARKET, BY DISEASE TYPE
CHAPTER 6: PRURITUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: PRURITUS THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
Companies Mentioned
Abbvie Inc.
Amgen Inc.
Bausch Health Companies Inc.
Cara Therapeutics, Inc.
Cipla Ltd.
Eilly Lilly and Company
Evelo Biosciences
Galderma S.A.
Leo Pharma
Mc2 Therapeuitics
Novan, Inc
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc
Sanofi
Trevi Therapeutics
Viatris Inc. (Mylan Nv)
For more information about this report visit https://www.researchandmarkets.com/r/y0fg4k
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
